Randomized Assessment of Rapid Endovascular Treatment of Ischemic Stroke
NEJM 372:1019-1030, Goyal, M.,et al, 2015
Stent-Retriever Thrombectomy after Intravenous t-PA vs. t-PA Alone in Stroke
NEJM 372:2285-2295,2347, Saver, J.L.,et al, 2015
Thrombectomy within 8 hours after Symptom Onset in Ischemic Stroke
NEJM 372:2296-2306,2347, Jovin, T.G.,et al, 2015
CT Angiography Findings in Carotid Blowout Syndrome and Its Role as a Predictor of 1-Year Survival
AJNR35:562-567, Lee, C-W.,et al, 2014
Computed Tomographic Angiography or Magnetic Resonance Angiography for Detection of Intracranial Vascular Malformations in Patients with Intracerebral Hemorrhage
Stroke 46:e2-e3, Josephson, C.B.,et al, 2014
Utility of MRI in Spinal Arteriovenous Fistula
Neruol 79:25-30,15, Toossi, S.,et al, 2012
Reversible Cerebral Vasoconstruction Syndromes
Arch Neurol 68:1005-1012,976, Singhal, A.B.,et al, 2011
Efficacy and Safety of Combination Antiplatelet Therapies in Patients with Symptomatic Intracranial Atherosclerotic Stenosis
Stroke 42:2883-2890, Kwon, S.U.,et al, 2011
Safety of Performing CT Angiography in Stroke Patients Treated With Intravenous Thrombolysis
JNNP 81:783-787, Aulick�,P., et al, 2010
Management of Stroke in Infants and Children: A Scientific Statement From a Special Writing Group of the American Heart Association Stroke Council and the Council on Cardiovascular Disease in the Young
Stroke 39:2644-2691, Roach,E.S.,et al., 2008
Inhibition of CD40L with Frexalimab in Multiple Sclerosis
NEJM 390:589-600, 662, Vermersch,P.,et al, 2024
Tirofiban for Stroke without Large or Medium-Sized Vessel Occlusion
NEJM 388:2025-2095, Zi,W.,et al, 2023
Lenvatinib Therapy for Advanced Thyroid Cancer: Real-Life Data on Safety, Efficacy, and Some Rare Side Effects
JENDSO 6:1-7, Hamidi, S.,et al, 2022
Hematopoietic Stem - and Progenitor-Cell Gene Therapy for Hurler Syndrome
NEJM 385:1929-1940, Gentner, B.,et al, 2021
Thrombolysis for Acute Ischemic Stroke in the Unwitnessed or Extended Therapeutic Time Window
Neurol 94:e1241-e1248, Tsivgoulis, G.,et al, 2020
Intravenous Alteplase for Stroke with Unknown Time of Onset Guided by Advanced Imaging:Systematic Review and Meta-Analysis of Individual Patient Data
Lancet 396:1574-1585, Thomalla,G.,et al, 2020
Multimodal CT or MRI for IV thrombolysis in ischemic stroke with unknown time of onset
Neurol 95:e2954-e2964, Macha, K.,et al, 2020
Thrombolysis Guided by Perfusion Imaging up to 9 Hours after Onset of Stroke
NEJM 380:1795-1803,1865, Ma, H.,et al, 2019
Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct
NEJM 378:11-22,81, Nogueira, R.G.,et al, 2018
MRI-Guided Thrombolysis for Stroke with Unknown Time of Onset
NEJM 379:611-622, 682, Thomalla, G.,et al, 2018
Intravenous Thrombolysis in Unwitnessed Stroke Onset: MR WITNESS Trial Results
Ann Neurol 83:980-993, Schwamm, L.H.,et al, 2018
Endovascular Treatment for Patients with Acute Stroke Who Have a Large Ischemic Core and Large Mismatch Imaging Profile
JAMA Neurol 74:34-40, Rebello, L.C.,et al, 2017
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
NEJM 376:221-234,280, Hauser, S.L.,et al, 2017
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
NEJM 376:209-220,280, Montalban, X.,et al, 2017
Alemtuzumab CARE-MS I 5-year follow-up
Neurol 89:1107-1116, Havrdova, E.,et al, 2017
Alemtuzumab CARE-MS II 5-year follow-up
Neurol 89:1117-1126, Coles, A.J.,et al, 2017
Computed Tomographic Perfusion to Predict Response to Recanalization in Ischemic Stroke
Ann Neurol 81:849-856, Lansberg, M.G.,et al, 2017
Favorable Bridging Therapy Based on DWI-FLAIR Mismatch in Patients with Unclear-Onset Stroke
AJNR 37:88-93, Mourand, I.,et al, 2016
Superior MRI Outcomes with Alemtuzumab Compared with Subcutaneous Interferon �-1a in MS
Neurol 87:1464-1472, Arnold, D.L.,et al, 2016
A Randomized Trial of Intraarterial Treatment for Acute Ischemic Stroke
NEJM 372:11-20,78, Berkhemer, O.A.,et al, 2015
Resective Epilepsy Surgery for Drug-Resistant Focal Epilepsy
JAMA 313:285-293, Jobst, B.C. & Cascino, G.D., 2015
Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis
NEJM 373:1418-1428, Kappos, L.,et al, 2015
Multimodal Diagnostic Imaging for Hyperacute Stroke
AJNR 36:2206-2213, Vo, K.D.,et al, 2015
Practice Guideline: Idiopathic Normal Pressure Hydrocephalus: Response to Shunting and Predictors of Response
Neurol 85:2063-2071, Halperin, J.J.,et al, 2015
Safety and Efficacy of Ofatumumab in Relapsing-Remitting Multiple Sclerosis
Neurol 82:573-581, Sorensen, P.S.,et al, 2014
Effect of Rituximab in Patients with Leucine-Rich, Glioma-Inactivated 1 Antibody-Associated Encephalopathy
JAMA Neurol 71:896-900, Irani, S.R.,et al, 2014
A Trial of Imaging Selection and Endovascular Treatment for Ischemic Stroke
NEJM 368:914-923,952, Kidwell, C.S.,et al, 2013
Endovascular Therapy after Intravenous t-PA versus t-PA Alone for Stroke
NEJM 368:893-903,952, Broderick, J.P.,et al, 2013
Daclizumab High-Yield Process in Relapsing-Remitting Multiple Sclerosis (SELECT): A Randomised, Double-Blind, Placebo-Controlled Trial
Lancet 381:2167-2175, Gold, R.,et al, 2013
Susceptibility-Weighted Imaging Is More Reliable Than T2*-Weighted Gradient-Recalled Echo MRI for Detecting Microbleeds
Stroke 44:2782-2786, Cheng, A.,et al, 2013
Impact of Fingolimod Therapy on Magnetic Resonance Imaging Outcomes in Patients with Multiple Sclerosis
Arch Neurol 69:1259-1269, Radue, E.W.,et al, 2012
Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
NEJM 367:1098-1106,1149, Gold, R.,et al, 2012
Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
NEJM 367:1087-1097,1149, Fox, R.J.,et al, 2012
Alemtuzumab for Multiples Sclerosis: Who and When to treat?
Lancet 380:1795-1797, 1792, Springer, T. & Kappos, L., 2012
Mechanisms of Fingolimods Efficacy and Adverse Effects in Multiple Sclerosis
Ann Neurol 69:759-777, Cohen, J.A. & Chun, J., 2011
Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
NEJM 365:1293-1303, OConnor, P.,et al, 2011
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
NEJM 362:402-415, 456, Cohen,J.A.,et al, 2010
A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis
NEJM 362:416-426, 456, Giovannoni,G.,et al, 2010
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
NEJM 362:387-401, 456, Kappos, L.,et al, 2010